Evidence map›Paper›PMID 41881025›Full record

ArticleCell reports. Medicine2026

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Richard J Lobb, Quan Zhou, David Fielding, Kekoolani S Visan, Alain Wuethrich, Jing Wang, Youran Hu, Emma L Norris, Marcus L Hastie, Sarah Everitt and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Richard J LobbAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia; Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia. Electronic address: richard.lobb@uq.edu.au.
Quan ZhouAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.
David FieldingDepartment of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD 4029, Australia.
Kekoolani S VisanJC STEM Lab, Department of Otorhinolaryngology, Chinese University of Hong Kong, Shatin, Hong Kong SAR; Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Shatin, Hong Kong SAR.
Alain WuethrichAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia.
Jing WangAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.
Youran HuAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia.
Emma L NorrisProtein Discovery Centre, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
Marcus L HastieProtein Discovery Centre, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
Sarah EverittDivision of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3052, Australia.
Brielle ParrisUQ Thoracic Research Centre, The University of Queensland, Brisbane, QLD 4072, Australia; The Prince Charles Hospital, Brisbane, QLD 4032, Australia.
Lauren G AoudeFrazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Vanessa F BonazziFrazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Elizabeth NixonDepartment of Thoracic Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD 4029, Australia.
Jennifer MooiOlivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.
Kevin M KooAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia; The University of Queensland Centre for Clinical Research (UQCCR), Brisbane, QLD 4029, Australia.
Kenneth O'ByrneSchool of Medicine, Queensland University of Technology, Brisbane, QLD 4102, Australia.
Arutha KulasingheFrazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Rayleen V BowmanUQ Thoracic Research Centre, The University of Queensland, Brisbane, QLD 4072, Australia; The Prince Charles Hospital, Brisbane, QLD 4032, Australia.
Ian A YangUQ Thoracic Research Centre, The University of Queensland, Brisbane, QLD 4072, Australia; The Prince Charles Hospital, Brisbane, QLD 4032, Australia.
Niall M CorcoranDepartment of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia; Division of Urology, Royal Melbourne Hospital, Melbourne, VIC 3052, Australia; Department of Urology, Peninsula Health, Melbourne, VIC 3199, Australia.
Christopher M HovensDepartment of Surgery, University of Melbourne, Melbourne, VIC 3010, Australia.
Michael MacManusDivision of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC 3052, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3052, Australia.
Jeffrey J GormanProtein Discovery Centre, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
Bryan W DaySid Faithfull Brain Cancer Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
Gunter HartelStatistics Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
David C WhitemanCancer Control Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.
Niall TebbuttOlivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.
John M MariadasonOlivia Newton-John Cancer Research Institute, Melbourne, VIC 3084, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC 3084, Australia.
Kwun M FongUQ Thoracic Research Centre, The University of Queensland, Brisbane, QLD 4072, Australia; The Prince Charles Hospital, Brisbane, QLD 4032, Australia.
Andrew P BarbourFrazer Institute, The University of Queensland, Brisbane, QLD 4102, Australia.
Matt TrauAustralian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia; School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072, Australia. Electronic address: m.trau@uq.edu.au.
Andreas MöllerTumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia; JC STEM Lab, Department of Otorhinolaryngology, Chinese University of Hong Kong, Shatin, Hong Kong SAR; Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Shatin, Hong Kong SAR. Electronic address: andreas.moeller@ent.cuhk.edu.hk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small extracellular vesicles (sEVs) offer a promising, non-invasive method for cancer detection. Despite global research efforts, successful translation of sEV-based diagnostics remains limited. In this study, we identify a 4-protein sEV biomarker panel (thrombospondin-1, nidogen-1, pentraxin-3, and versican) based on proteomic profiles obtained from an isogenic cancer cell line model. The panel's performance is validated across 22 cancer cell lines and 764 retrospective plasma/serum samples spanning multiple cancer types, yielding robust performance (area under the curve [AUC]: 0.91-1.00). To facilitate clinical application, we develop a multiplex sEV device that integrates nanoshearing-based microfluidics and surface-enhanced Raman scattering (SERS) for simultaneous detection of the 4-protein panel. Using this device on a prospective cohort of 68 patients, we accurately differentiate between benign lung changes and early-stage lung cancer. These findings underscore the potential of sEVs as diagnostic markers for cancer screening. Furthermore, the multiplex microfluidic device's scalability, simplicity, and cost-effectiveness indicate feasibility for large-scale population screening.

Indexed as

Biomarkers, TumorEarly Detection of CancerExtracellular VesiclesLung NeoplasmsNeoplasmsCell Line, TumorFemaleHumansMaleProteomicsSpectrum Analysis, RamanBiomarkers, Tumorextracellular vesiclesliquid biopsylung cancer screeningmicrofluidicsminiaturized biosensormulti-cancer early diagnosissurface-enhanced Raman spectroscopy

Identifiers

PMID41881025
PMCPMC13130687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.